Using magnets to fight cancer

FeRx Inc. is hoping that a single Phase II/III trial of its MTC-DOX magnetic targeted carrier formulation of doxorubicin will be sufficient for U.S. registration. The company is banking that its technology for site-specific administration to liver tumors will increase efficacy while reducing the serious cardiovascular side effects of doxorubicin.

Last week FeRx reported that in a U.S. Phase I/II dose-ranging trial in 33 patients with hepatocellular carcinoma (HCC), there was one complete response, two partial responses, and seven minor responses in 21 lesions in 19 patients. Seven patients had stable disease and four had progressive disease. ...